CMTM2 expression in human testicular cancer tissues by tissue microarray analysis

Zhenhua Liu,Tao Xu,Yunbei Xiao,Xiaowei Zhang,Yongping Zhao,Xiaofeng Wang
DOI: https://doi.org/10.3969/j.issn.1008-0848.2011.03.001
2011-01-01
Abstract:Objective To investigate the expression of CMTM2 in human testicular cancer tissues and its clinicopathological significance. Methods The expressions of CMTM2 in testicular cancer tissues and normal testis tissues were detected by immunohistochemistry. Results Immunohistochemistry analysis showed that 73.3% (11/15) of normal testis tissues, 65.4%(17/26) of seminoma tissues, 57.1%(4/7) of teratoma tissues, 25.0%(3/12) of embryonal carcinoma tissues, and 40.0% (4/10) of yolk sac tumor tissues had positive expression of CMTM2. The expression levels of CMTM2 in embryonal carcinoma tissues and yolk sac tumor tissues were significantly lower than that of the normal control (P<0.05, respectively), but those of seminoma tissues and teratoma tissues had no significant differences (P> 0.05,respectively). Conclusion Low expressions of CMTM2 in embryonal carcinoma tissues and yolk sac tumor tissues suggested that CMTM2 might be a cancer suppressor candidate gene.
What problem does this paper attempt to address?